Adicet Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, advancing an “off‑the‑shelf ...

Adicet Bio ( (ACET)) just unveiled an announcement. On December 19, 2025, Adicet Bio, Inc. held a Special Meeting of Stockholders at which investors approved an amendment to the company’s Restated ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest update is out from Adicet Bio ...

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Adicet Bio, Inc. (NASDAQ:ACET) stands against ...

Adicet Bio (NASDAQ:ACET – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Adicet Bio to post earnings of ($0.36) ...

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in shares of Adicet Bio during the fourth quarter worth ...

Cell therapy developer Adicet Bio (NASDAQ:ACET) has reprioritized its resources to focus its lead candidate, ADI-001, on autoimmune indications. The decision has prompted the company to discontinue ...

Multiple analysts have issued price targets for $ACET recently. We have seen 2 analysts offer price targets for $ACET in the last 6 months, with a median target of $5 ...

The average one-year price target for Adicet Bio (NasdaqCM:ACET) has been revised to $7.75 / share. This is an increase of 20.00% from the prior estimate of $6.46 dated November 7, 2025. The price ...